FIM
JNCE

Freedom Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Freedom Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-49,959
Closed -$417K – 985
2021
Q4 		$417K Buy
49,959
+19,320
+63% +$159K 0.03% 583
2021
Q3 		$228K Buy
30,639
+1,420
+5% +$8.8K 0.02% 717
2021
Q2 		$199K Buy
29,219
+10,800
+59% +$89.7K 0.01% 828
2021
Q1 		$189K Buy
+18,419
New +$202K 0.01% 797

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Freedom Investment Management's JNCE Position: Q1 2022 in Review

Freedom Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 49,959 shares — an estimated $417K sold.

Freedom Investment Management first reported a position in JNCE in Q1 2021 and held it in 4 quarters. The position peaked at $417K in Q4 2021. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Freedom Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Freedom Investment Management sold 49,959 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $417K.
  • Freedom Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Freedom Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $417K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Freedom Investment Management's 13F filing for Q1 2022, filed 16 May 2022.